{"id":"NCT02016105","sponsor":"Sandoz","briefTitle":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira","officialTitle":"A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2015-07","completion":"2016-02","firstPosted":"2013-12-19","resultsPosted":"2017-04-07","lastUpdate":"2017-05-30"},"enrollment":465,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Type Psoriasis"],"interventions":[{"type":"DRUG","name":"GP2017 Adalimumab","otherNames":[]},{"type":"DRUG","name":"Humira ® Adalimumab","otherNames":[]}],"arms":[{"label":"GP2017 Adalimumab","type":"EXPERIMENTAL"},{"label":"Humira ® Adalimumab","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study is to demonstrate equivalent efficacy and similarity in the safety profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type psoriasis.","primaryOutcome":{"measure":"PASI 75 Response Rate at Week 16 - GP2017 Adalimumab vs Humira ® Adalimumab","timeFrame":"At Week 16 only","effectByArm":[{"arm":"GP2017 Adalimumab","deltaMin":66.8,"sd":null},{"arm":"Humira ® Adalimumab","deltaMin":65,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":79,"countries":["United States","Bulgaria","France","Slovakia"]},"refs":{"pmids":["39545451","33651341"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":63},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Sinusitis","Arthralgia"]}}